Regencell Bioscience Holdings Limited (RGC)
USD 30.49
(5.87%)
USD 30.49
(5.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -3.61 Million USD | 31.65% |
| 2023 | -5.29 Million USD | 21.52% |
| 2022 | -6.99 Million USD | -417.63% |
| 2021 | -1.35 Million USD | -68.76% |
| 2020 | -802.85 Thousand USD | -105.34% |
| 2019 | -390.99 Thousand USD | -100.08% |
| 2018 | 468.7 Million USD | -8.51% |
| 2017 | 512.3 Million USD | 8.93% |
| 2016 | 470.3 Million USD | 20.28% |
| 2015 | 391 Million USD | 0.0% |
| 2013 | 469.2 Million USD | 11.13% |
| 2012 | 422.2 Million USD | 19.77% |
| 2011 | 352.5 Million USD | -31.17% |
| 2010 | 512.1 Million USD | 156.05% |
| 2009 | 200 Million USD | 0.0% |
| 2007 | 676 Million USD | 214.42% |
| 2006 | 215 Million USD | -2.27% |
| 2005 | 220 Million USD | -43.88% |
| 2004 | 392 Million USD | 0.0% |
| 2002 | 401 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -2.17 Million USD | 0.0% |
| 2024 Q2 | -1082.64 USD | -101.9% |
| 2024 Q1 | -1082.64 USD | 45.21% |
| 2023 FY | - USD | 21.52% |
| 2023 Q1 | -1677.22 USD | 99.95% |
| 2023 Q2 | -3.42 Million USD | -204376.09% |
| 2023 Q4 | -2.07 Million USD | -149730.38% |
| 2023 Q3 | -1384.54 USD | 99.96% |
| 2022 Q3 | -1972.82 USD | 99.95% |
| 2022 Q4 | -3.35 Million USD | -169933.93% |
| 2022 FY | - USD | -417.63% |
| 2022 Q1 | -1822.84 USD | -264.65% |
| 2022 Q2 | -3.65 Million USD | -200625.9% |
| 2021 FY | - USD | -68.76% |
| 2021 Q3 | -499.89 USD | -181.53% |
| 2021 Q4 | -499.89 USD | -0.0% |
| 2021 Q2 | -177.56 USD | 0.0% |
| 2021 Q1 | -177.56 USD | 30.31% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | - USD | -105.34% |
| 2020 Q4 | -254.80 USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | - USD | -100.08% |
| 2018 FY | - USD | -8.51% |
| 2018 Q2 | 132.7 Million USD | 53.59% |
| 2018 Q1 | 86.4 Million USD | -17.32% |
| 2017 Q4 | 104.5 Million USD | -25.36% |
| 2017 Q3 | 140 Million USD | -2.3% |
| 2017 Q2 | 143.3 Million USD | 10.23% |
| 2017 Q1 | 130 Million USD | 15.15% |
| 2017 FY | - USD | 8.93% |
| 2016 Q4 | 112.9 Million USD | -10.47% |
| 2016 FY | - USD | 20.28% |
| 2016 Q3 | 126.1 Million USD | -14.22% |
| 2016 Q2 | 147 Million USD | 64.98% |
| 2016 Q1 | 89.1 Million USD | -37.08% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | 141.6 Million USD | 52.92% |
| 2015 Q2 | 131.5 Million USD | 34.46% |
| 2015 Q3 | 92.6 Million USD | -29.58% |
| 2015 Q1 | 97.8 Million USD | -9.78% |
| 2014 Q4 | 108.4 Million USD | 103.38% |
| 2014 Q2 | 91.2 Million USD | -48.56% |
| 2014 Q1 | 177.3 Million USD | 54.17% |
| 2014 Q3 | 53.3 Million USD | -41.56% |
| 2013 Q4 | 115 Million USD | 34.19% |
| 2013 FY | - USD | 11.13% |
| 2013 Q2 | 108.9 Million USD | 27.52% |
| 2013 Q1 | 85.4 Million USD | -21.44% |
| 2013 Q3 | 85.7 Million USD | -21.3% |
| 2012 Q4 | 108.7 Million USD | -8.81% |
| 2012 FY | - USD | 19.77% |
| 2012 Q1 | 88.4 Million USD | -18.82% |
| 2012 Q2 | 45.8 Million USD | -48.19% |
| 2012 Q3 | 119.2 Million USD | 160.26% |
| 2011 Q3 | 14.1 Million USD | -81.23% |
| 2011 FY | - USD | -31.17% |
| 2011 Q1 | 119.9 Million USD | -8.91% |
| 2011 Q2 | 75.1 Million USD | -37.36% |
| 2011 Q4 | 108.9 Million USD | 672.34% |
| 2010 Q1 | 8 Million USD | -90.12% |
| 2010 FY | - USD | 156.05% |
| 2010 Q4 | 131.63 Million USD | 180.07% |
| 2010 Q3 | 47 Million USD | -56.24% |
| 2010 Q2 | 107.4 Million USD | 1242.5% |
| 2009 Q2 | 68 Million USD | -10.53% |
| 2009 Q3 | 47 Million USD | -30.88% |
| 2009 Q1 | 76 Million USD | 80.95% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | 81 Million USD | 72.34% |
| 2008 Q1 | 115 Million USD | 6.48% |
| 2008 Q4 | 42 Million USD | 200.0% |
| 2008 Q3 | 14 Million USD | -74.07% |
| 2008 Q2 | 54 Million USD | -53.04% |
| 2007 FY | - USD | 214.42% |
| 2007 Q1 | 67 Million USD | 36.73% |
| 2007 Q2 | 63 Million USD | -5.97% |
| 2007 Q3 | 399 Million USD | 533.33% |
| 2007 Q4 | 108 Million USD | -72.93% |
| 2006 Q2 | 77 Million USD | 50.98% |
| 2006 Q3 | 36 Million USD | -53.25% |
| 2006 FY | - USD | -2.27% |
| 2006 Q4 | 49 Million USD | 36.11% |
| 2006 Q1 | 51 Million USD | -58.2% |
| 2005 Q4 | 122 Million USD | 22.98% |
| 2005 FY | - USD | -43.88% |
| 2005 Q1 | 119.8 Million USD | 134.9% |
| 2005 Q2 | 70 Million USD | -41.57% |
| 2005 Q3 | 99.2 Million USD | 41.71% |
| 2004 Q3 | 69 Million USD | -69.47% |
| 2004 Q1 | 91 Million USD | 49.18% |
| 2004 Q2 | 226 Million USD | 148.35% |
| 2004 Q4 | 51 Million USD | -26.09% |
| 2004 FY | - USD | 0.0% |
| 2003 Q4 | 61 Million USD | -42.45% |
| 2003 Q2 | 229 Million USD | 110.09% |
| 2003 Q3 | 106 Million USD | -53.71% |
| 2003 Q1 | 109 Million USD | 100.4% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | -27.58 Billion USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 406.06% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 101.173% |
| Journey Medical Corporation | 1.92 Million USD | 288.32% |
| Dynavax Technologies Corporation | 9.66 Million USD | 137.426% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 97.59% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 97.723% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 102.221% |
| PainReform Ltd. | -9.56 Million USD | 62.194% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 14.109% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 5.407% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 5.407% |
| SCYNEXIS, Inc. | 73.47 Million USD | 104.923% |
| Silver Spike Investment Corp. | 7.34 Million USD | 149.286% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -53.875% |
| Alpha Teknova, Inc. | -25.53 Million USD | 85.835% |
| Alvotech | -484.86 Million USD | 99.254% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 103.309% |
| Bright Green Corporation | - USD | Infinity% |
| Embecta Corp. | 245.4 Million USD | 101.474% |
| Safety Shot Inc | -12.18 Million USD | 70.311% |
| Procaps Group, S.A. | 104.02 Million USD | 103.478% |
| Cosmos Health Inc. | -17.06 Million USD | 78.797% |
| Theratechnologies Inc. | -10.31 Million USD | 64.921% |
| Harrow Health, Inc. | 9.72 Million USD | 137.207% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 20.052% |
| Biofrontera Inc. | -18.45 Million USD | 80.395% |
| DURECT Corporation | -24.68 Million USD | 85.344% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 103.682% |
| Cronos Group Inc. | -72.14 Million USD | 94.986% |
| OptiNose, Inc. | -15.55 Million USD | 76.74% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.609% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 89.974% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 113.773% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 110.04% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 7.769% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -408.916% |
| Radius Health, Inc. | 38.31 Million USD | 109.443% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -12.521% |
| ProPhase Labs, Inc. | -14.82 Million USD | 75.601% |
| Phibro Animal Health Corporation | 84.6 Million USD | 104.276% |
| Procaps Group S.A. | 104.02 Million USD | 103.478% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 56.938% |
| Viatris Inc. | 3.51 Billion USD | 100.103% |
| Rockwell Medical, Inc. | -4.69 Million USD | 22.931% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -257.473% |
| SIGA Technologies, Inc. | 84.15 Million USD | 104.299% |
| Tilray Brands, Inc. | -72.84 Million USD | 95.034% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 545.521% |
| Shineco, Inc. | -26.55 Million USD | 86.376% |
| PetIQ, Inc. | 81.48 Million USD | 104.44% |
| Incannex Healthcare Limited | -18.5 Million USD | 80.449% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.869% |
| Alimera Sciences, Inc. | 7.27 Million USD | 149.72% |
| Assertio Holdings, Inc. | -222.44 Million USD | 98.374% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 9.347% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 78.472% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 81.94% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 97.574% |
| Hempacco Co., Inc. | -12.77 Million USD | 71.678% |
| Talphera, Inc. | -9.84 Million USD | 63.243% |
| Alvotech | -484.86 Million USD | 99.254% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 104.668% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.737% |
| Currenc Group, Inc. | -1.9 Million USD | -90.344% |
| Kamada Ltd. | 21.53 Million USD | 116.8% |
| Indivior PLC | 66 Million USD | 105.481% |
| Evoke Pharma, Inc. | -7.29 Million USD | 50.391% |
| Flora Growth Corp. | -45.87 Million USD | 92.113% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 81.94% |
| Evolus, Inc. | -41.81 Million USD | 91.347% |
| HUTCHMED (China) Limited | 25.52 Million USD | 114.171% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 101.498% |
| Akanda Corp. | -27.73 Million USD | 86.957% |